Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Investments (2016 - 2023)

ImmunityBio (IBRX) has disclosed Long-Term Investments for 10 consecutive years, with $891000.0 as the latest value for Q4 2023.

  • Quarterly Long-Term Investments rose 6.07% to $891000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $891000.0 through Dec 2023, up 6.07% year-over-year, with the annual reading at $891000.0 for FY2023, 6.07% up from the prior year.
  • Long-Term Investments for Q4 2023 was $891000.0 at ImmunityBio, up from $817000.0 in the prior quarter.
  • The five-year high for Long-Term Investments was $9.3 million in Q2 2020, with the low at $769000.0 in Q3 2020.
  • Average Long-Term Investments over 5 years is $2.0 million, with a median of $865000.0 recorded in 2022.
  • The sharpest move saw Long-Term Investments skyrocketed 527.11% in 2020, then crashed 91.16% in 2021.
  • Over 5 years, Long-Term Investments stood at $1.5 million in 2019, then tumbled by 36.54% to $950000.0 in 2020, then decreased by 13.47% to $822000.0 in 2021, then rose by 2.19% to $840000.0 in 2022, then rose by 6.07% to $891000.0 in 2023.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $891000.0, $817000.0, and $841000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.